TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor

Madrigal Pharmaceuticals announced an exclusive global license agreement with Pfizer to develop ervogastat, a Phase 2 oral DGAT-2 inhibitor for MASH treatment. The deal includes a $50 million upfront payment to Pfizer, with ervogastat positioned as a complementary therapy to Madrigal's approved drug Rezdiffra for potential combination treatment. Madrigal plans to conduct drug-to-drug interaction studies and consult with the FDA on Phase 2 combination trial design in 2026.

Insights
CB   positive

Increased position by 16%, buying 4.3 million new shares


MDGL   positive

Madrigal secured an exclusive global license for a promising Phase 2 asset (ervogastat) that complements its approved drug Rezdiffra, strengthening its pipeline and positioning the company for combination therapy development. This strategic expansion demonstrates confidence in the company's MASH treatment leadership and provides multiple value creation opportunities through milestone payments and royalties.